levofloxacin has been researched along with itraconazole in 12 studies
Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (itraconazole) | Trials (itraconazole) | Recent Studies (post-2010) (itraconazole) |
---|---|---|---|---|---|
4,346 | 581 | 2,209 | 249 | 4 | 108 |
Protein | Taxonomy | levofloxacin (IC50) | itraconazole (IC50) |
---|---|---|---|
Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.89 | |
ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.7 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.666 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.4256 | |
ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 0.2 | |
C-X-C chemokine receptor type 1 | Homo sapiens (human) | 2.5676 | |
Cruzipain | Trypanosoma cruzi | 3 | |
Vasopressin V2 receptor | Homo sapiens (human) | 3.476 | |
C-C chemokine receptor type 4 | Homo sapiens (human) | 3.2689 | |
Lanosterol 14-alpha demethylase | Homo sapiens (human) | 3.6 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (41.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Güzeldemirci, NU; Küçükbasmaci, O | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bortolozzo, Lde S; de Castro Siqueira, AM; Jorge, SD; Palace-Berl, F; Pasqualoto, KF; Tavares, LC; Zorzi, RR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gao, F; Huang, G; Xiao, J | 1 |
2 review(s) available for levofloxacin and itraconazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current scenario of tetrazole hybrids for antibacterial activity.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Tetrazoles | 2019 |
10 other study(ies) available for levofloxacin and itraconazole
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synthesis and antimicrobial activity evaluation of new 1,2,4-triazoles and 1,3,4-thiadiazoles bearing imidazo[2,1-b]thiazole moiety.
Topics: Anti-Infective Agents; Fungi; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Radiometry; Thiadiazoles; Triazoles; Xanthenes | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Cross Infection; Dose-Response Relationship, Drug; Fungi; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrofurans; Principal Component Analysis; Structure-Activity Relationship | 2014 |